首页> 美国卫生研究院文献>Journal of Radiation Research >Proposal for determining absolute biological effectiveness of boron neutron capture therapy—the effect of 10B(nα)7Li dose can be predicted from the nucleocytoplasmic ratio or the cell size
【2h】

Proposal for determining absolute biological effectiveness of boron neutron capture therapy—the effect of 10B(nα)7Li dose can be predicted from the nucleocytoplasmic ratio or the cell size

机译:确定硼中子俘获疗法绝对生物学有效性的建议-可以从核质比或细胞大小预测10B(nα)7Li剂量的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The relationship between the radiation dose delivered to a tumor and its effect is not completely predictable. Uncertainty in the estimation of the boron concentration in a tumor, variation in the radiation sensitivity of the tumor cells, and the complexity of the interactions between the four types of radiation comprising the boron neutron capture therapy (BNCT) dose contribute to this uncertainty. We reanalyzed the data of our previous papers to investigate the variation in radiosensitivity of tumor cells to the 10B(n,α)7Li dose: the dose generated by the reaction of thermal neutrons and 10B, hereafter the ‘boron-neutron dose’. The radiosensitivities of five tumors (EL4, SASeo, SAS/mp53, SCCVII and B16-BL6 melanoma) were examined. For the combination of p-boron-L-phenylalanine (BPA: C9H12BNO4) with neutron irradiation, D0, the cell survival curve for the boron-neutron dose was the smallest for the SASeo, followed by the EL4, SAS/mp53, SCCVII and B16-BL6 melanoma, in that order. For the combination of mercaptoundecahydrododecaborate (BSH: Na2B12H11SH) with neutron irradiation, D0 was the smallest for the EL4, followed by the SASeo, B16–BL6melanoma, SAS/mp53 and SCCVII, in that order. The relationships between these D0 values and the nucleocytoplasmic ratios (Xncs) or cell size indices (Xcs) obtained by histopathological microslide image were as follows: (D0 = 0.1341Xnc–1.586, R2 = 0.9721) for all tumor types with BPA-BNCT, and D0 = 0.0122Xcs–0.1319 (R2 = 0.9795) for four tumor types (all except the B16-BL6 melanoma) with BSH-BNCT. Based on these results, we proposed a new biologically equivalent effectiveness factor: the absolute biological effectiveness (ABE) factor. The ABE factor is Gy/D0. Thus, the ABE dose is the physical dose multiplied by the ABE factor, and refers to the dose needed to decrease the cell survival rate to e–ABE dose/Gy.
机译:传递到肿瘤的辐射剂量与其效果之间的关系尚无法完全预测。估计肿瘤中硼浓度的不确定性,肿瘤细胞辐射敏感性的变化以及包括硼中子俘获疗法(BNCT)剂量在内的四种辐射类型之间相互作用的复杂性,造成了这种不确定性。我们重新分析了先前论文的数据,以研究肿瘤细胞对 10 B(n,α) 7 Li剂量的放射敏感性的变化:反应产生的剂量热中子和 10 B,此后称为“硼中子剂量”。检查了五种肿瘤(EL4,SAS / neo,SAS / mp53,SCCVII和B16-BL6黑色素瘤)的放射敏感性。对于p-硼-L-苯丙氨酸(BPA:C9H12BNO4)与中子辐射D0的组合,对于SAS / neo,硼中子剂量的细胞存活曲线最小,其次是EL4,SAS / mp53, SCCVII和B16-BL6黑色素瘤按该顺序排列。对于巯基十二氢十二硼酸盐(BSH:Na2B12H11SH)与中子辐射的组合,D4对于EL4最小,其次是SAS / neo,B16-BL6黑色素瘤,SAS / mp53和SCCVII。这些D0值与通过组织病理学微幻灯片图像获得的核质比(Xncs)或细胞大小指数(Xcs)之间的关系如下:(D0 = 0.1341Xnc –1.586 ,R 2 < / sup> = 0.9721)适用于所有BPA-BNCT类型的肿瘤,D0 = 0.0122Xcs–0.1319(R 2 = 0.9795)适用于四种BSH-BNCT类型肿瘤(除B16-BL6黑色素瘤以外) -BNCT。基于这些结果,我们提出了一个新的生物学等效有效性因子:绝对生物学有效性(ABE)因子。 ABE因子为Gy / D0。因此,ABE剂量是物理剂量乘以ABE因子,是指将细胞存活率降低至e –ABE剂量/ Gy 所需的剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号